PTC Therapeutics Sets FDA Target Date For Sepiapterin NDA Review And Publishes Phase 3 Trial Results
PTC Therapeutics Inc. (PTCT) announced that the FDA has set a target action date of July 29, 2025, for the review of the New Drug ...
Buy Rating Affirmed for PTC Therapeutics on Sepiapterin’s Strong Regulatory and Clinical Prospects for PKU Treatment
William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on September 26. Sami Corwin has ...
Monthly Prescribing Reference21d
FDA to Review Sepiapterin for Treatment of Phenylketonuria
Long-term data showed patients treated with sepiapterin maintained mean blood Phe control while significantly increasing protein intake. The Food and Drug Administration (FDA) has accepted for ...
Morningstar7d
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
"The Lancet publication reflects the promising and transformative nature of the data collected to date on sepiapterin and the therapy's potential to fill the persistent and significant unmet ...
PTC Therapeutics brain disorder therapy granted FDA review
PTC Therapeutics (NASDAQ:PTCT) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted its marketing ...
Nasdaq20d
PTC Therapeutics Reports Filing Acceptance For Sepiapterin - Quick Facts
(RTTNews) - PTC Therapeutics (PTCT) announced the FDA has accepted for filing the New Drug Application of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria.
WKRN-TV20d
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of ...
PTC Therapeutics Announces FDA Target Regulatory Action Date For Sepiapterin And Lancet Publication Of Phase 3 Trial Results
"The Lancet publication reflects the promising and transformative nature of the data collected to date on sepiapterin and the therapy's potential to fill the persistent and significant unmet medical ...